He Jiankui

He Jiankui
Name	He Jiankui
Birth date	1984
Birth place	Hunan, China
Nationality	Chinese
Fields	Biophysics, Genetics, Molecular biology
Alma mater	Xidian University; Rice University; University of Science and Technology of China
Known for	Gene-editing controversy

He Jiankui was a Chinese researcher who became internationally known for announcing the birth of genome-edited infants using CRISPR. His work provoked intense debate among scientists, ethicists, regulators, and political leaders across China and the United States. The announcement catalyzed revisions to policy at institutions including World Health Organization, National Institutes of Health, and Chinese regulatory bodies.

Early life and education

Born in Hunan province, He Jiankui studied electrical engineering at Xidian University before moving to the United States for graduate study. He completed a Ph.D. at Rice University and did postdoctoral work at Stanford University and the University of Science and Technology of China. During his training he interacted with researchers at Broad Institute, MIT, and Harvard University, and attended conferences hosted by Cold Spring Harbor Laboratory and International Summit on Human Gene Editing.

Career and research

He worked at Shenzhen-based institutions, including collaborations with laboratories affiliated with Southern University of Science and Technology and Shenzhen Harmonicare Women and Children's Hospital. His research portfolio included projects related to HIV/AIDS prevention and gene-editing techniques employing CRISPR-Cas9 systems developed by teams at University of California, Berkeley and EMBL. He participated in workshops organized by Chinese Academy of Sciences and engaged with companies in the biotech clusters of Shenzhen and Guangzhou. Colleagues and collaborators included investigators from Peking University, Tsinghua University, University of California, Los Angeles, and the Bill & Melinda Gates Foundation-funded initiatives.

CRISPR gene-editing experiment and announcement

In 2018 He announced at the Second International Summit on Human Genome Editing in Hong Kong that twin girls had been born after embryos were edited to modify the CCR5 gene using CRISPR-Cas9. The claim referenced protocols similar to those described by laboratories at Broad Institute, MIT, and Harvard Medical School. The announcement met rapid coverage from outlets such as Nature (journal), Science (journal), The New York Times, and The Wall Street Journal. The work invoked prior studies on CCR5-Δ32 allele frequency in European Union populations and drew comparisons to gene therapies approved by agencies like the U.S. Food and Drug Administration and European Medicines Agency.

Ethical, legal, and scientific responses

Scientific communities including the National Academy of Sciences (United States), Royal Society, European Society of Human Genetics, and the World Health Organization condemned the lack of transparent oversight and peer review. Bioethicists at Johns Hopkins University, Oxford University, and University of Cambridge highlighted concerns about informed consent and long-term follow-up. Regulatory responses involved institutions such as the Ministry of Science and Technology (China), National Health Commission (China), U.S. National Institutes of Health, and legislative bodies including the Standing Committee of the National People's Congress. Journals and societies including Nature Biotechnology and the International Society for Stem Cell Research reaffirmed moratoria and governance frameworks.

Investigations, trials, and sentencing

Chinese authorities, including the Guangdong Provincial Health Commission and prosecutors in Shenzhen, launched investigations. He was detained and later tried in court in Shenzhen for illegal medical practice. The court sentenced him to prison and imposed fines; the verdict paralleled actions by professional bodies such as Chinese Academy of Medical Sciences and prompted institutional dismissals at centers affiliated with Southern University of Science and Technology. International responses included calls for criminal investigations from members of European Commission research committees and statements from the United Nations Educational, Scientific and Cultural Organization.

Impact and legacy on gene-editing policy

The incident accelerated policy development across institutions: the World Health Organization established a governance framework for human genome editing, the National Institutes of Health and U.S. Food and Drug Administration reiterated funding and clinical trial restrictions, and Chinese authorities revised regulations governing assisted reproductive technology and biotech oversight. Academic programs at Harvard Medical School, Stanford University School of Medicine, Peking University Health Science Center, and Tsinghua University expanded curricula in bioethics and governance. International summits, including meetings convened by the Royal Society and National Academy of Medicine, adopted more stringent recommendations for transparent review, data sharing, and moratoria on clinical germline editing.

Category:Chinese scientists